Company Profile
Akili Interactive
Company Overview
Akili Interactive (www.akiliinteractive.com) is aiming to commercialize an entirely new class of medical product that combines rigorous scientific validation with engaging video game mechanics. We are creating the next-generation of cognitive assessments and neural therapeutics (what we call “Digital Medicine”T) based on cutting-edge neuroscience and validated by clinical trials. Akili's flagship product, the Project: EVO platform, is based on technology developed at UCSF that was featured as the cover article in Nature in September 2013, under the headline "Game Changer".
Akili was founded by leading neuroscientists and top-tier game design veterans to create gaming experiences that are designed to have measurable health impacts in multiple patient populations. Akili has done deals with top pharmaceutical companies, and has received recent recognition in major media outlets including the Wall Street Journal, CNBC, Fast Company, and The Verge.
Company History
The science behind our first platform, "Project: EVO", was developed at the University of California, San Francisco by Dr. Adam Gazzaley, Founding Director of the UCSF Neuroscience Imaging Center and Akili's Chief Science Advisor. Dr. Gazzaley's research has led to a patent-pending new software-based method to measure and improve a key system of executive function known as "interference processing." We've deployed these mechanics from the ground up in a consumer video game engine that runs on mobile phones and tablets, and meets all requirements for rigorous clinical studies. The Project: EVO platform is currently being tested in a variety of clinical studies in multiple patient populations around the globe, including ADHD, autism, depression, and traumatic brain injury.